Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis

Ying Li; Tingting Cao; Chao Shen; Rongqin Dai; Yi Su; Yanxia Li; Cuicui Wang; Guiran Yang; Zhenjiang Hou

doi:doi:10.11648/j.ajcem.20210906.18

| Peer-Reviewed

Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis

Ying Li, Tingting Cao, Chao Shen, Rongqin Dai, Yi Su, Yanxia Li, Cuicui Wang, Guiran Yang, Zhenjiang Hou

Published in American Journal of Clinical and Experimental Medicine (Volume 9, Issue 6)

Received: 7 January 2022 Accepted: Published: 8 January 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Object: To investigate the levels of serum interleukin-10 (IL-10) and IL-17 in papillary thyroid carcinoma (PTC) and their relationship with prognosis. Method: 120 PTC patients who underwent radical mastectomy in the Department of Thyroid and Mammary Surgery of Cangzhou Central Hospital from January 2018 to April 2019 were randomly selected as the experimental group, and 120 healthy people who matched 1:1 with the hospital physical examination center in the same period were selected as the control group according to the sex, age and body mass index of the experimental group. Compare the levels of serum IL-10 and IL-17 between the two groups, analyze the relationship between the levels and the pathological features of PTC patients, draw the characteristic curve of subjects' working characteristics, and calculate the area under the curve (AUC) to evaluate the diagnostic value of serum IL-10 and IL-17 for PTC. All patients were followed up for 12 months after operation. Imaging and pathological examination results were used as prognostic indicators. Kaplan-Meier survival analysis was used to analyze the relationship between serum IL-10 and IL-17 levels and the prognosis of PTC patients. COX regression analysis was used to analyze the prognostic factors of PTC patients. Result: The levels of serum IL-10 and IL-17 in experimental group were significantly higher than those in control group (P<0.05). Comparison of serum IL-10 levels in PTC patients with different tumor diameters and lymphatic metastasis showed statistically significant difference (P<0.05). The level of IL-17 in serum of PTC patients with different TNM stages, differentiation degree and lymphatic metastasis was statistically significant (P<0.05). The diagnostic value of serum IL-10 combined with IL-17 in PTC is significantly higher than that of single detection (P<0.05). According to the median serum IL-10 and IL-17 for PTC diagnosis, the postoperative recurrence rate of IL-10 high expression group was significantly higher than that of IL-10 low expression group, and the postoperative recurrence rate of IL-17 high expression group was significantly higher than that of IL-17 low expression group (P<0.05). TNM stage, IL-10 level and IL-17 level are independent risk factors for postoperative recurrence of PTC patients (P<0.05). Conclusion: The elevated levels of serum IL-10 and IL-17 in PTC patients are related to TNM stage, degree of differentiation, maximum tumor diameter and lymphatic metastasis, and are independent risk factors for postoperative recurrence of PTC patients, which may be a reference index for disease diagnosis and prognosis evaluation.

Published in	American Journal of Clinical and Experimental Medicine (Volume 9, Issue 6)
DOI	10.11648/j.ajcem.20210906.18
Page(s)	238-245
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Papillary Thyroid Carcinoma, Interleukin 10, Interleukin 17, Diagnosis, Prognosis

References

[1]	Selek A, Cetinarslan B, Tarkun I, et al. Thyroid autoimmunity: is really associated with papillary thyroid carcinoma?[J]. European Archives of Oto-Rhino-Laryngology, 2017, 274 (3): 1677-1681.
[2]	Haiyu Yang, Yong Liu. Diagnosis and differential diagnosis of papillary thyroid carcinoma [J]. Journal of Clinical and Experimental Pathology, 2017, 33 (6): 658-663.
[3]	Hughes N M, Nae A, Barry J, et al. Sonographic differences between conventional and follicular variant papillary thyroid carcinoma [J]. European Archives of Oto-Rhino-Laryngology, 2017, 274 (7): 1-7.
[4]	Hong Y R, Lee S H, Lim D J, et al. The stratification of patient risk depending on the size and ratio of metastatic lymph nodes in papillary thyroid carcinoma [J]. World Journal of Surgical Oncology, 2017, 15 (1): 74.
[5]	Barilla R M, Diskin B, Caso R C, et al. Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma [J]. Nature Communications, 2019, 10 (1).
[6]	Xinglian Jiang, Hui Zhang, Yanlin Chen, et al. Expression and correlation of microRNA-221 and interleukin-17 in papillary thyroid carcinoma [J]. Chinese Journal of Pathology, 2017, 46 (3): 6.
[7]	Liyan Li, Xiaojie Wang, Wenwen Wang, et al. The expression and significance of interleukin-10 and chemokine receptor 7 in papillary thyroid carcinoma tissues [J]. Chinese Journal of Endocrine Surgery, 2020, 14 (1): 32-36.
[8]	Bo Zhang, Jingzhu Xu, Qiong Wu. Interpretation of the 2015 American Thyroid Association "Guidelines for the Diagnosis and Treatment of Adult Thyroid Nodules and Differentiated Thyroid Cancer": Ultrasound Part [J]. Chinese Journal of Cancer, 2016, 26 (1): 19-24.
[9]	Valvo V, Nucera C. Coding Molecular Determinants of Thyroid Cancer Development and Progression [J]. Endocrinology and metabolism clinics of North America, 2018.
[10]	Weibin Wang, XingyunSu, JiayingRuan, et al. Clinicopathological and prognostic analysis of 2682 cases of papillary thyroid carcinoma [J]. Chinese Journal of General Surgery, 2018, 33 (5): 393-397.
[11]	Jinlang Huang, Yihui Weng, Hengwei Zhang, et al. Progress in clinical diagnosis and treatment of papillary thyroid carcinoma [J]. Chinese Journal of Clinical Research, 2020, 33 (2): 246-248.
[12]	Chunjing Ning, Shuanglong Wang, Bin Lu. Progress in the clinical application of ultrasound imaging combined with serological examination and genetic testing for papillary thyroid microcarcinoma [J]. Journal of Imaging Research and Medical Applications, 2021, 5 (8): 1-2.
[13]	Rong Yang, Jun Ren. Meta analysis of the relationship between IL-17 and IL-35 levels and thyroid cancer [J]. Labeled Immunoassays and Clinics, 2017 (5): 513-515, 533.
[14]	Haiyan Kang, Tingxian Yang, Lei Zhang. The changes and significance of serum Gal-3, IL-17, IL-35, anti-TgAb in patients with thyroid cancer [J]. Medical Journal of National Defending Forces in Northwest China, 2017, 38 (8): 505-508.
[15]	Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer [J]. Breast Cancer Research and Treatment, 2012, 133 (1): 11-21.
[16]	Kurte M, Lopez M, Aguirre A, et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells [J]. Journal of Immunology, 2004, 173 (3): 1731-1737.
[17]	Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses [J]. Annual Review of Immunology, 2004, 22 (22): 531-562.
[18]	Qing Zhu, Qiuxia Ren, Lei Wu, etc. The expression and clinical significance of regulatory T cells and related inflammatory factors in colon cancer [J]. Chinese Journal of Medical Frontiers (Electronic Edition), 2017, 9 (11): 29-32.
[19]	Xiaoli Liu, Zhiming Yang, Wang Lili, et al. Correlation analysis between ovarian cancer cell metastasis and T lymphocyte subsets imbalance in tissues and peripheral blood [J]. Chinese Journal of Postgraduates of Medicine, 2017, 40 (5): 390-394.
[20]	Xie S, Li J, Wang J H, et al. IL-17 Activates the Canonical NF-kappaB Signaling Pathway in Autoimmune B Cells of BXD2 Mice to Upregulate the Expression of Regulators of G-Protein Signaling 16 [J]. Journal of Immunology, 2010, 184 (5): 2289-2296.
[21]	Roussel L, Houle F, Chan C, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation [J]. Journal of Immunology, 2010, 184 (8): 4531-7.
[22]	Meyer D M, Jesson M I, Xiong L, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis [J]. Journal of Inflammation, 2010, 7 (1): 41.
[23]	Hurtado C G, Wan F, Housseau F, et al. Roles for interleukin 17 andadaptive immunity in pathogenesis of colorectal cancer [J]. Gastroenterology, 2018, 1555 (6): 1706-1715.
[24]	Xin Y M, Chang H Z, Ma J, et al. Expression of interleukin-17 and its clinical significance in gastric cancer patients [J]. Medical Oncology, 2012, 29 (5): 3024-3028.
[25]	Xiaoyu Zhang, JinlingZuo, Gu Li, et al. The value of miR-200 a combined with carbohydrate antigen 125 and interleukin-17 in the early diagnosis of epithelial ovarian cancer [J]. China Family Planning and Obstetrics and Gynecology, 2020, 12 (1): 64-68.
[26]	Cunningham D, Zhang Q, Liu S, et al. Interleukin-17 promotes metas-tasis in an immunocompetent orthotopic mouse model of prostate cancer [J]. Am J Clin Exp Urol. 2018. 6 (3): 114-122.
[27]	Liao R, Sun J, Wu H, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma [J]. Journal of Experimental & Clinical Cancer Research, 2013, 32 (1): 3-3.
[28]	Kang Mao, Jianbo Xu, Yanmin Yang, JieQiu, Jingshuang Wang. The application value of Galectin-3 and IL-17 in the diagnosis of thyroid cancer [J]. Journal of Qiqihar Medical College, 2018, 39 (03): 326-327.
[29]	Jianzhong Wang, Yuanyang Wang. Expression levels and clinical significance of inflammatory factors in thyroid cancer [J]. International Journal of Geriatrics, 2019, 40 (1): 29-31.
[30]	JieLi, HanyuZhu, ZeweiYu, et al. Application value of combined detection of molecular markers based on BRAFV600E in prognostic evaluation of papillary thyroid carcinoma [J]. Basic Medicine and Clinics, 2018, 38 (10): 1470-1474.

Cite This Article

Plain Text BibTeX RIS

APA Style

Ying Li, Tingting Cao, Chao Shen, Rongqin Dai, Yi Su, et al. (2022). Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis. American Journal of Clinical and Experimental Medicine, 9(6), 238-245. https://doi.org/10.11648/j.ajcem.20210906.18

Copy | Download

ACS Style

Ying Li; Tingting Cao; Chao Shen; Rongqin Dai; Yi Su, et al. Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis. Am. J. Clin. Exp. Med. 2022, 9(6), 238-245. doi: 10.11648/j.ajcem.20210906.18

Copy | Download

AMA Style

Ying Li, Tingting Cao, Chao Shen, Rongqin Dai, Yi Su, et al. Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis. Am J Clin Exp Med. 2022;9(6):238-245. doi: 10.11648/j.ajcem.20210906.18

Copy | Download

@article{10.11648/j.ajcem.20210906.18,
  author = {Ying Li and Tingting Cao and Chao Shen and Rongqin Dai and Yi Su and Yanxia Li and Cuicui Wang and Guiran Yang and Zhenjiang Hou},
  title = {Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {9},
  number = {6},
  pages = {238-245},
  doi = {10.11648/j.ajcem.20210906.18},
  url = {https://doi.org/10.11648/j.ajcem.20210906.18},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210906.18},
  abstract = {Object: To investigate the levels of serum interleukin-10 (IL-10) and IL-17 in papillary thyroid carcinoma (PTC) and their relationship with prognosis. Method: 120 PTC patients who underwent radical mastectomy in the Department of Thyroid and Mammary Surgery of Cangzhou Central Hospital from January 2018 to April 2019 were randomly selected as the experimental group, and 120 healthy people who matched 1:1 with the hospital physical examination center in the same period were selected as the control group according to the sex, age and body mass index of the experimental group. Compare the levels of serum IL-10 and IL-17 between the two groups, analyze the relationship between the levels and the pathological features of PTC patients, draw the characteristic curve of subjects' working characteristics, and calculate the area under the curve (AUC) to evaluate the diagnostic value of serum IL-10 and IL-17 for PTC. All patients were followed up for 12 months after operation. Imaging and pathological examination results were used as prognostic indicators. Kaplan-Meier survival analysis was used to analyze the relationship between serum IL-10 and IL-17 levels and the prognosis of PTC patients. COX regression analysis was used to analyze the prognostic factors of PTC patients. Result: The levels of serum IL-10 and IL-17 in experimental group were significantly higher than those in control group (P<0.05). Comparison of serum IL-10 levels in PTC patients with different tumor diameters and lymphatic metastasis showed statistically significant difference (P<0.05). The level of IL-17 in serum of PTC patients with different TNM stages, differentiation degree and lymphatic metastasis was statistically significant (P<0.05). The diagnostic value of serum IL-10 combined with IL-17 in PTC is significantly higher than that of single detection (P<0.05). According to the median serum IL-10 and IL-17 for PTC diagnosis, the postoperative recurrence rate of IL-10 high expression group was significantly higher than that of IL-10 low expression group, and the postoperative recurrence rate of IL-17 high expression group was significantly higher than that of IL-17 low expression group (P<0.05). TNM stage, IL-10 level and IL-17 level are independent risk factors for postoperative recurrence of PTC patients (P<0.05). Conclusion: The elevated levels of serum IL-10 and IL-17 in PTC patients are related to TNM stage, degree of differentiation, maximum tumor diameter and lymphatic metastasis, and are independent risk factors for postoperative recurrence of PTC patients, which may be a reference index for disease diagnosis and prognosis evaluation.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis
AU  - Ying Li
AU  - Tingting Cao
AU  - Chao Shen
AU  - Rongqin Dai
AU  - Yi Su
AU  - Yanxia Li
AU  - Cuicui Wang
AU  - Guiran Yang
AU  - Zhenjiang Hou
Y1  - 2022/01/08
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20210906.18
DO  - 10.11648/j.ajcem.20210906.18
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 238
EP  - 245
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20210906.18
AB  - Object: To investigate the levels of serum interleukin-10 (IL-10) and IL-17 in papillary thyroid carcinoma (PTC) and their relationship with prognosis. Method: 120 PTC patients who underwent radical mastectomy in the Department of Thyroid and Mammary Surgery of Cangzhou Central Hospital from January 2018 to April 2019 were randomly selected as the experimental group, and 120 healthy people who matched 1:1 with the hospital physical examination center in the same period were selected as the control group according to the sex, age and body mass index of the experimental group. Compare the levels of serum IL-10 and IL-17 between the two groups, analyze the relationship between the levels and the pathological features of PTC patients, draw the characteristic curve of subjects' working characteristics, and calculate the area under the curve (AUC) to evaluate the diagnostic value of serum IL-10 and IL-17 for PTC. All patients were followed up for 12 months after operation. Imaging and pathological examination results were used as prognostic indicators. Kaplan-Meier survival analysis was used to analyze the relationship between serum IL-10 and IL-17 levels and the prognosis of PTC patients. COX regression analysis was used to analyze the prognostic factors of PTC patients. Result: The levels of serum IL-10 and IL-17 in experimental group were significantly higher than those in control group (P<0.05). Comparison of serum IL-10 levels in PTC patients with different tumor diameters and lymphatic metastasis showed statistically significant difference (P<0.05). The level of IL-17 in serum of PTC patients with different TNM stages, differentiation degree and lymphatic metastasis was statistically significant (P<0.05). The diagnostic value of serum IL-10 combined with IL-17 in PTC is significantly higher than that of single detection (P<0.05). According to the median serum IL-10 and IL-17 for PTC diagnosis, the postoperative recurrence rate of IL-10 high expression group was significantly higher than that of IL-10 low expression group, and the postoperative recurrence rate of IL-17 high expression group was significantly higher than that of IL-17 low expression group (P<0.05). TNM stage, IL-10 level and IL-17 level are independent risk factors for postoperative recurrence of PTC patients (P<0.05). Conclusion: The elevated levels of serum IL-10 and IL-17 in PTC patients are related to TNM stage, degree of differentiation, maximum tumor diameter and lymphatic metastasis, and are independent risk factors for postoperative recurrence of PTC patients, which may be a reference index for disease diagnosis and prognosis evaluation.
VL  - 9
IS  - 6
ER  -

Copy | Download

Author Information

Ying Li

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Tingting Cao

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Chao Shen

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Rongqin Dai

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Yi Su

Thyroid and Breast Surgical Department, People's Hospital of Nanpi County, Cangzhou, China
Yanxia Li

Department of Rheumatology and Immunology, Cangzhou Central Hospital, Cangzhou, China
Cuicui Wang

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Guiran Yang

Department of Medical Technology, Cangzhou Medical College, Cangzhou, China
Zhenjiang Hou

Institute of Thyroid Diseases Affiliated to Cangzhou Medical College, Cangzhou Thyroid Disease Engineering Technology Research Center, Cangzhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ying Li, Tingting Cao, Chao Shen, Rongqin Dai, Yi Su, et al. (2022). Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis. American Journal of Clinical and Experimental Medicine, 9(6), 238-245. https://doi.org/10.11648/j.ajcem.20210906.18

Copy | Download

ACS Style

Ying Li; Tingting Cao; Chao Shen; Rongqin Dai; Yi Su, et al. Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis. Am. J. Clin. Exp. Med. 2022, 9(6), 238-245. doi: 10.11648/j.ajcem.20210906.18

Copy | Download

AMA Style

Ying Li, Tingting Cao, Chao Shen, Rongqin Dai, Yi Su, et al. Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis. Am J Clin Exp Med. 2022;9(6):238-245. doi: 10.11648/j.ajcem.20210906.18

Copy | Download

@article{10.11648/j.ajcem.20210906.18,
  author = {Ying Li and Tingting Cao and Chao Shen and Rongqin Dai and Yi Su and Yanxia Li and Cuicui Wang and Guiran Yang and Zhenjiang Hou},
  title = {Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {9},
  number = {6},
  pages = {238-245},
  doi = {10.11648/j.ajcem.20210906.18},
  url = {https://doi.org/10.11648/j.ajcem.20210906.18},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210906.18},
  abstract = {Object: To investigate the levels of serum interleukin-10 (IL-10) and IL-17 in papillary thyroid carcinoma (PTC) and their relationship with prognosis. Method: 120 PTC patients who underwent radical mastectomy in the Department of Thyroid and Mammary Surgery of Cangzhou Central Hospital from January 2018 to April 2019 were randomly selected as the experimental group, and 120 healthy people who matched 1:1 with the hospital physical examination center in the same period were selected as the control group according to the sex, age and body mass index of the experimental group. Compare the levels of serum IL-10 and IL-17 between the two groups, analyze the relationship between the levels and the pathological features of PTC patients, draw the characteristic curve of subjects' working characteristics, and calculate the area under the curve (AUC) to evaluate the diagnostic value of serum IL-10 and IL-17 for PTC. All patients were followed up for 12 months after operation. Imaging and pathological examination results were used as prognostic indicators. Kaplan-Meier survival analysis was used to analyze the relationship between serum IL-10 and IL-17 levels and the prognosis of PTC patients. COX regression analysis was used to analyze the prognostic factors of PTC patients. Result: The levels of serum IL-10 and IL-17 in experimental group were significantly higher than those in control group (P<0.05). Comparison of serum IL-10 levels in PTC patients with different tumor diameters and lymphatic metastasis showed statistically significant difference (P<0.05). The level of IL-17 in serum of PTC patients with different TNM stages, differentiation degree and lymphatic metastasis was statistically significant (P<0.05). The diagnostic value of serum IL-10 combined with IL-17 in PTC is significantly higher than that of single detection (P<0.05). According to the median serum IL-10 and IL-17 for PTC diagnosis, the postoperative recurrence rate of IL-10 high expression group was significantly higher than that of IL-10 low expression group, and the postoperative recurrence rate of IL-17 high expression group was significantly higher than that of IL-17 low expression group (P<0.05). TNM stage, IL-10 level and IL-17 level are independent risk factors for postoperative recurrence of PTC patients (P<0.05). Conclusion: The elevated levels of serum IL-10 and IL-17 in PTC patients are related to TNM stage, degree of differentiation, maximum tumor diameter and lymphatic metastasis, and are independent risk factors for postoperative recurrence of PTC patients, which may be a reference index for disease diagnosis and prognosis evaluation.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Serum Interleukin-10 and Interleukin-17 Levels in Papillary Carcinoma and Their Relationship with Prognosis
AU  - Ying Li
AU  - Tingting Cao
AU  - Chao Shen
AU  - Rongqin Dai
AU  - Yi Su
AU  - Yanxia Li
AU  - Cuicui Wang
AU  - Guiran Yang
AU  - Zhenjiang Hou
Y1  - 2022/01/08
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20210906.18
DO  - 10.11648/j.ajcem.20210906.18
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 238
EP  - 245
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20210906.18
AB  - Object: To investigate the levels of serum interleukin-10 (IL-10) and IL-17 in papillary thyroid carcinoma (PTC) and their relationship with prognosis. Method: 120 PTC patients who underwent radical mastectomy in the Department of Thyroid and Mammary Surgery of Cangzhou Central Hospital from January 2018 to April 2019 were randomly selected as the experimental group, and 120 healthy people who matched 1:1 with the hospital physical examination center in the same period were selected as the control group according to the sex, age and body mass index of the experimental group. Compare the levels of serum IL-10 and IL-17 between the two groups, analyze the relationship between the levels and the pathological features of PTC patients, draw the characteristic curve of subjects' working characteristics, and calculate the area under the curve (AUC) to evaluate the diagnostic value of serum IL-10 and IL-17 for PTC. All patients were followed up for 12 months after operation. Imaging and pathological examination results were used as prognostic indicators. Kaplan-Meier survival analysis was used to analyze the relationship between serum IL-10 and IL-17 levels and the prognosis of PTC patients. COX regression analysis was used to analyze the prognostic factors of PTC patients. Result: The levels of serum IL-10 and IL-17 in experimental group were significantly higher than those in control group (P<0.05). Comparison of serum IL-10 levels in PTC patients with different tumor diameters and lymphatic metastasis showed statistically significant difference (P<0.05). The level of IL-17 in serum of PTC patients with different TNM stages, differentiation degree and lymphatic metastasis was statistically significant (P<0.05). The diagnostic value of serum IL-10 combined with IL-17 in PTC is significantly higher than that of single detection (P<0.05). According to the median serum IL-10 and IL-17 for PTC diagnosis, the postoperative recurrence rate of IL-10 high expression group was significantly higher than that of IL-10 low expression group, and the postoperative recurrence rate of IL-17 high expression group was significantly higher than that of IL-17 low expression group (P<0.05). TNM stage, IL-10 level and IL-17 level are independent risk factors for postoperative recurrence of PTC patients (P<0.05). Conclusion: The elevated levels of serum IL-10 and IL-17 in PTC patients are related to TNM stage, degree of differentiation, maximum tumor diameter and lymphatic metastasis, and are independent risk factors for postoperative recurrence of PTC patients, which may be a reference index for disease diagnosis and prognosis evaluation.
VL  - 9
IS  - 6
ER  -

Copy | Download